How are generic prices changing, how will biosimilars impact costs, and what changes out of Washington should healthcare executives watch? Economics guru Joe Fuhr weighs in.
Pharmacy Best Practices
Oncology Institute’s Dawn Holcombe, MBA, FACMPE, ACHE, shares her views on the OCM program, what CAR T-cell therapy means for the future of reimbursement, and some epic predictions.
Director of medication safety and quality for the American Society of Health-System Pharmacists shares how providers can better work with pharmacists to address the opioid epidemic.
Find out what challenges top the list, and what analysts say can be done about them.
This might be the year when it becomes clear, perhaps painfully so, whether or not biosimilars can deliver on cost savings expectations.
More targeted therapies for autoimmune diseases are on the horizon. Here’s what to anticipate in 2018.
The winds of change swept through healthcare in 2017. Here’s what 2018 could bring.
PBMs are in a unique position to help curb opioid abuse. Here are four programs that demonstrate promising outcomes.
Shocking opioid overdose statistics make it crucial to address the epidemic. Here are four programs to watch
A Walgreens study sheds light on the benefits of patient-centered pharmacy-based programs.